Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Expression and Its Correlation with Prognosis and Growth of Serous Ovarian Cancer: Correlation of DYRK3 with Ovarian Cancer Survival

Table 2

Overall survival analyses of SOC patients.

Variables	Cases ()	OS (months)	3-year OS	value
		Age (years)						0.084
≤60 yrs	153		85.0%
>60 yrs	101		68.8%
Laterality				<0.001
Unilateral	190		83.1%
Bilateral	64		63.6%
Lymph node status				<0.001
Negative	156		87.6%
Positive	98		64.5%
FIGO stage				<0.001
Stage I-II	79		98.6%
Stage III	126		74.7%
Stage IV	49		48.7%
Chemotherapy				0.628
Yes	137		78.8%
No	117		79.6%
DYRK3 expression				<0.001
Low	127		92.1%
High	127		65.4%

Abbreviations: LN: lymph node; SOC: serous ovarian cancer; DYRK3: dual-specificity tyrosine phosphorylation-regulated kinase 3; FIGO: International Federation of Gynecology and Obstetrics. Note: data was tested by two-sided log-rank test. indicates .